Why fund managers see Dimerix's trial delay as a de-risking move

Dimerix extended its Phase 3 kidney disease trial timeline in favour of a more traditional approval pathway, which fund managers view as increasing the odds of eventual success.

16 Jul 2026 · 5 min read

Rare kidney disease drug developer Dimerix saw the timeline for its Phase 3 ACTION3 trial extended after a blinded statistical review, with SG Hiscock & Company's April 2026 Monthly Report confirming the study remains appropriately powered, above 90%, to demonstrate a treatment effect on its primary proteinuria endpoint, even as the decision to continue through to the final endpoint pushed out the potential readout timeline.

A more de-risked path traded for a longer timeline

SG Hiscock's report framed the decision as a prudent strategic outcome: by prioritising a traditional approval pathway over an accelerated approach, Dimerix and its commercial partners are effectively increasing the probability of regulatory success while reducing execution and approval risk, particularly relevant given the evolving regulatory acceptance of proteinuria as a primary endpoint in focal segmental glomerulosclerosis, the rare kidney disease the drug targets. The report noted the decision reflected alignment with Dimerix's licensing partners, who are economically incentivised toward maximising ultimate approval probability rather than near-term timing.

While the upside remains and we retain confidence in a positive outcome, the timing has been pushed out... If anything, I think the odds of success have improved and we are just dealing with a longer timeframe.

— Yarra Capital Management, Article, July 2026

Yarra Capital Management's July 2026 Article confirmed the manager's continued conviction despite the delay, noting Dimerix continues to successfully pursue licensing deals, most recently with Everest Medicines covering Greater China, South Korea and South-East Asia, validating commercial interest in the program even as the accelerated approval pathway was set aside. SG Hiscock's report also flagged a funding solution in progress, with the company's most recent quarterly update highlighting advanced discussions for up to approximately US$50 million in non-dilutive financing that, if executed, would provide additional flexibility to fund the program through to completion.

What managers are watching next

Yarra Capital Management's January 2026 Article had earlier described the stock as high risk, high reward, liking both the product and the team addressing a rare disease end market genuinely in need of new treatment options. With the extended trial timeline now the base case and non-dilutive financing discussions ongoing, Yarra's stated approach is to hold the position and look for opportunities to add on any significant weakness, rather than treating the timeline delay as a reason to exit.